AU743788B2 - Method of improving disturbed behavior and elevating mood in humans - Google Patents

Method of improving disturbed behavior and elevating mood in humans Download PDF

Info

Publication number
AU743788B2
AU743788B2 AU72916/98A AU7291698A AU743788B2 AU 743788 B2 AU743788 B2 AU 743788B2 AU 72916/98 A AU72916/98 A AU 72916/98A AU 7291698 A AU7291698 A AU 7291698A AU 743788 B2 AU743788 B2 AU 743788B2
Authority
AU
Australia
Prior art keywords
dronabinol
dementia
administration
medicament
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU72916/98A
Other languages
English (en)
Other versions
AU7291698A (en
Inventor
Ladislav Volicer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unimed Pharmaceuticals LLC
Original Assignee
Unimed Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/866,511 external-priority patent/US5804592A/en
Application filed by Unimed Pharmaceuticals LLC filed Critical Unimed Pharmaceuticals LLC
Publication of AU7291698A publication Critical patent/AU7291698A/en
Assigned to UNIMED PHARMACEUTICALS, INC. reassignment UNIMED PHARMACEUTICALS, INC. Amend patent request/document other than specification (104) Assignors: UNIMED PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU743788B2 publication Critical patent/AU743788B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU72916/98A 1997-05-07 1998-05-06 Method of improving disturbed behavior and elevating mood in humans Ceased AU743788B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4581397P 1997-05-07 1997-05-07
US60/045813 1997-05-07
US08/866511 1997-05-30
US08/866,511 US5804592A (en) 1997-05-30 1997-05-30 Method for improving disturbed behavior and elevating mood in humans
PCT/US1998/009269 WO1998050027A1 (en) 1997-05-07 1998-05-06 Method of improving disturbed behavior and elevating mood in humans

Publications (2)

Publication Number Publication Date
AU7291698A AU7291698A (en) 1998-11-27
AU743788B2 true AU743788B2 (en) 2002-02-07

Family

ID=26723227

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72916/98A Ceased AU743788B2 (en) 1997-05-07 1998-05-06 Method of improving disturbed behavior and elevating mood in humans

Country Status (6)

Country Link
EP (1) EP1019041A4 (ja)
JP (1) JP2002501510A (ja)
AU (1) AU743788B2 (ja)
CA (1) CA2288693A1 (ja)
IL (1) IL132784A (ja)
WO (1) WO1998050027A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138094A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92238A (en) * 1989-11-07 1995-07-31 Yissum Res Dev Co ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists

Also Published As

Publication number Publication date
IL132784A (en) 2004-07-25
EP1019041A4 (en) 2002-04-17
CA2288693A1 (en) 1998-11-12
WO1998050027A1 (en) 1998-11-12
EP1019041A1 (en) 2000-07-19
IL132784A0 (en) 2001-03-19
AU7291698A (en) 1998-11-27
JP2002501510A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
US5804592A (en) Method for improving disturbed behavior and elevating mood in humans
Volicer et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease
RU2281771C2 (ru) Использование декстрометорфана и ингибитора оксидазы для отучения пациентов от наркотиков и антидепрессантов
Robinson et al. Sodium oxybate: a review of its use in the management of narcolepsy
TW201900158A (zh) 使用氟苯丙胺治療杜希氏徵候群之方法
AU2024220039A1 (en) Treatment of fragile X syndrome with cannabidiol
US20100178362A1 (en) Chromium complexes for improvement of memory and cognitive function
US12128021B1 (en) Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Playfer Parkinson's disease
Thorpe The treatment of psychotic disorders in late life
KR100530879B1 (ko) 알카노일 카르니틴 유도체를 함유한 주의력-결핍 및 과잉행동 장애 치료용 약제조성물
Lai et al. Selecting a medical therapy for overactive bladder
EP4157236A1 (en) Treatment of autism spectrum disorder with cannabidiol
AU743788B2 (en) Method of improving disturbed behavior and elevating mood in humans
WO1992018005A1 (en) Method of treating trichotillomania and onychophagia
WO2001074339A2 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
MXPA99010187A (en) Method of improving disturbed behavior and elevating mood in humans
US5863925A (en) Use of sulbutiamine in the treatment of Parkinson's disease, schizophrenia, alcoholism, and dysthymia
Tablets Prescribing information
US20240366548A1 (en) Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
US20240366547A1 (en) Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
Hoffer Allergy, depression and tricyclic antidepressants
Safer Drug treatment in child psychiatry
US9877951B2 (en) Method for treating dementia

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: UNIMED PHARMACEUTICALS, INC.

Free format text: FORMER NAME: UNIMED PHARMACEUTICAL, INC.

FGA Letters patent sealed or granted (standard patent)
SREP Specification republished